<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Syndromic forms of hyperinsulinism</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Syndromic forms of hyperinsulinism</h1>
<div class="graphic"><div class="figure"><div class="ttl">Syndromic forms of hyperinsulinism</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="17%"></colgroup><colgroup width="32%"></colgroup> <tbody> <tr> <td class="subtitle1">Syndrome</td> <td class="subtitle1">Gene</td> <td class="subtitle1">Locus</td> <td class="subtitle1">Inheritance</td> <td class="subtitle1">Features</td> </tr> <tr> <td> <p>Beckwith-Wiedemann<sup>[1]</sup></p> <a href="https://omim.org/entry/130650" target="_blank">MIM #130650</a></td> <td><em><a href="https://omim.org/entry/103280" target="_blank">H19</a></em>; <em><a href="https://omim.org/entry/616186" target="_blank">IGF2</a>;</em> <em><a href="https://omim.org/entry/604115" target="_blank">KCNQ1</a></em>; <em><a href="https://omim.org/entry/600856" target="_blank">CDKN1C</a></em></td> <td>11p15</td> <td>Complex – Can be autosomal dominant, contiguous gene duplication at 11p15, or genomic imprinting</td> <td>Macroglossia, abdominal wall defects, lateralized overgrowth, embryonal tumors</td> </tr> <tr class="highlight_lght_gray_text"> <td> <p>Kabuki<sup>[2]</sup></p> <a href="https://omim.org/entry/147920" target="_blank">MIM #147920</a>;<br/> <a href="https://omim.org/entry/300867" target="_blank">MIM #300867</a></td> <td><em><a href="https://omim.org/entry/602113" target="_blank">KMT2D</a></em>; <em><a href="https://omim.org/entry/300128" target="_blank">KDM6A</a></em></td> <td> <p>12q13</p> Xp.11</td> <td>Dominant</td> <td>Characteristic facial features – Eversion of lower lateral eyelid, arched eyebrows, depressed nasal tip, and prominent ears; fetal finger pads; short stature; skeletal abnormalities; cardiac defects; intellectual disability</td> </tr> <tr> <td> <p>Sotos<sup>[3]</sup></p> <a href="https://omim.org/entry/117550" target="_blank">MIM #117550</a></td> <td><em><a href="https://omim.org/entry/606681" target="_blank">NSD1</a></em></td> <td>5q35</td> <td>Dominant</td> <td>Prenatal and postnatal overgrowth, frontal bossing, intellectual disability</td> </tr> <tr class="highlight_lght_gray_text"> <td>Turner<sup>[4]</sup></td> <td><em><a href="https://omim.org/entry/300128" target="_blank">KDM6A</a></em>? (in association with monosomy X)</td> <td>X</td> <td>Sporadic</td> <td>Short stature, premature ovarian failure, congenital heart defects, kidney abnormalities, autoimmune thyroiditis</td> </tr> <tr> <td>Hyperinsulinism with hypopituitarism<sup>[5]</sup></td> <td><em><a href="https://omim.org/entry/600288" target="_blank">FOXA2</a></em></td> <td>20p11</td> <td>Dominant</td> <td>Hypopituitarism, dysmorphic facial features, hypoplastic pituitary gland and stalk</td> </tr> <tr class="highlight_lght_gray_text"> <td>Hyperinsulinism with polycystic kidneys<sup>[6]</sup></td> <td><em><a href="https://omim.org/entry/601785" target="_blank">PMM2</a></em></td> <td>16p13</td> <td>Recessive<sup>*</sup></td> <td>Polycystic kidney disease, liver cysts</td> </tr> <tr> <td> <p>Tyrosinemia type 1<sup>[7]</sup></p> <a href="https://omim.org/entry/276700" target="_blank">MIM #276700</a></td> <td><em><a href="https://omim.org/entry/613871" target="_blank">FAH</a></em></td> <td>15q25</td> <td>Recessive</td> <td>Liver dysfunction, renal tubular dysfunction, rickets, growth failure</td> </tr> <tr class="highlight_lght_gray_text"> <td> <p>Usher syndrome type IC<sup>[8]</sup></p> <a href="https://omim.org/entry/276904" target="_blank">MIM #276904</a></td> <td><em><a href="https://omim.org/entry/600509" target="_blank">ABCC8</a></em>; <em><a href="https://omim.org/entry/600937" target="_blank">KCNJ11</a></em><sup>¶</sup></td> <td>11p15</td> <td>Recessive</td> <td>Sensorineural deafness, vestibular hypofunction, retinitis pigmentosa, enteropathy</td> </tr> <tr> <td> <p>Rubinstein-Taybi<sup>[9]</sup></p> <a href="https://omim.org/entry/180849" target="_blank">MIM #180849</a>;<br/> <a href="https://omim.org/entry/613684" target="_blank">MIM# 613684</a></td> <td><em><a href="https://omim.org/entry/600140" target="_blank">CREBBP</a></em>; <em><a href="https://omim.org/entry/602700" target="_blank">EP300</a></em></td> <td> <p>22q13</p> 16p13</td> <td>Dominant</td> <td>Distal limb abnormalities, short stature, intellectual disabilities</td> </tr> <tr class="highlight_lght_gray_text"> <td colspan="5">Congenital disorders of glycosylation</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1"> <p>Phosphomannomutase 2 deficiency<sup>[10]</sup></p> <a href="https://omim.org/entry/212065" target="_blank">MIM #212065</a></td> <td><em><a href="https://omim.org/entry/601785" target="_blank">PMM2</a></em></td> <td>16p13</td> <td>Recessive</td> <td>Failure to thrive, developmental delay, epilepsy, ataxia, hepatopathy</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1"> <p>Mannosephosphate isomerase deficiency<sup>[11]</sup></p> <a href="https://omim.org/entry/602579" target="_blank">MIM #602579</a></td> <td><em><a href="https://omim.org/entry/154550" target="_blank">MPI</a></em></td> <td>15q24</td> <td>Recessive</td> <td>Failure to thrive, protein-losing enteropathy, hepatopathy</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1"> <p>Phosphoglucomutase 1 deficiency<sup>[12]</sup></p> <a href="https://omim.org/entry/614921" target="_blank">MIM #614921</a></td> <td><em><a href="https://omim.org/entry/171900" target="_blank">PGM1</a></em></td> <td>1p31</td> <td>Recessive</td> <td>Cleft lip, bifid uvula, hepatopathy, short stature</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>* Promotor mutation (c.-167G&gt;T) either homozygous or in trans with coding mutation.</p>
<p>¶ Contiguous gene deletion of 11p14-15, which includes part of <em>ABCC8</em> and encompassing the Usher gene locus (<a href="https://omim.org/entry/605242" target="_blank"><em>USH1C</em></a>).</p></div><div class="graphic_reference">References:
<ol>
<li>Brioude F, Kalish JM, Mussa A, et al. Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith-Wiedemann syndrome: an international consensus statement. Nat Rev Endocrinol 2018; 14:229.</li>
<li>Yap KL, Johnson AEK, Fischer D, et al. Congenital hyperinsulinism as the presenting feature of Kabuki syndrome: clinical and molecular characterization of 9 affected individuals. Genet Med 2019; 21:233.</li>
<li>Matsuo T, Ihara K, Ochiai M, et al. Hyperinsulinemic hypoglycemia of infancy in Sotos syndrome. Am J Med Genet A 2013; 161a:34.</li>
<li>Gibson CE, Boodhansingh KE, Li C, et al. Congenital Hyperinsulinism in Infants with Turner Syndrome: Possible Association with Monosomy X and KDM6A Haploinsufficiency. Horm Res Paediatr 2018; 89:413.</li>
<li>Giri D, Vignola ML, Gualtieri A, et al. Novel FOXA2 mutation causes Hyperinsulinism, Hypopituitarism with Craniofacial and Endoderm-derived organ abnormalities. Hum Mol Genet 2017; 26:4315.</li>
<li>Flanagan SE, Kapoor RR, Mali G, et al. Diazoxide-responsive hyperinsulinemic hypoglycemia caused by HNF4A gene mutations. Eur J Endocrinol 2010; 162:987.</li>
<li>Baumann U, Preece MA, Green A, Kelly DA, McKiernan PJ. Hyperinsulinism in tyrosinaemia type I. J Inherit Metab Dis 2005; 28:131.</li>
<li>Bitner-Glindzicz M, Lindley KJ, Rutland P, et al. A recessive contiguous gene deletion causing infantile hyperinsulinism, enteropathy and deafness identifies the Usher type 1C gene. Nat Genet 2000; 26:56.</li>
<li>Welters A, Meissner T, Grulich-Henn J, et al. Characterization of diabetes following pancreatic surgery in patients with congenital hyperinsulinism. Orphanet J Rare Dis 2018; 13:230.</li>
<li>Shanti B, Silink M, Bhattacharya K, et al. Congenital disorder of glycosylation type Ia: heterogeneity in the clinical presentation from multivisceral failure to hyperinsulinaemic hypoglycaemia as leading symptoms in three infants with phosphomannomutase deficiency. J Inherit Metab Dis 2009; 32:S241.</li>
<li>de Lonlay P, Cuer M, Vuillaumier-Barrot S, et al. Hyperinsulinemic hypoglycemia as a presenting sign in phosphomannose isomerase deficiency: A new manifestation of carbohydrate-deficient glycoprotein syndrome treatable with mannose. J Pediatr 1999; 135:379.</li>
<li>Tegtmeyer LC, Rust S, van Scherpenzeel M, et al. Multiple phenotypes in phosphoglucomutase 1 deficiency. N Engl J Med 2014; 370:533.</li>
</ol></div><div id="graphicVersion">Graphic 127893 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
